Ticker LaunchUplisting · SNBP
Panbela Therapeutics, Inc.
Formerly Sun BioPharma, Inc.; Cimarron Medical, Inc.; CIMARRON SOFTWARE INC
Panbela Therapeutics, Inc. (SNBP), already reporting to the SEC, moved up to Nasdaq Capital Market on Aug 31, 2020 with an offering at $4.12 per share. Craig-Hallum was lead-left underwriter. Faegre Drinker advised the company and Ellenoff Grossman & Schole advised the underwriters.
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing SBP-101, a small molecule polyamine metabolic inhibitor given by subcutaneous injection for pancreatic cancer and other solid tumors. It has FDA Fast Track designation and is first targeting metastatic pancreatic ductal adenocarcinoma.
- Status
- Uplisting
- Ticker
- SNBP
- Exchange
- Nasdaq Capital Market
- Listed
- Aug 31, 2020
- Price
- $4.12
- Market cap at IPO price
- $39.7M
- First filed
- May 14, 2012
- Underwriters
- Craig-Hallum
- Company counsel
- Faegre Drinker
- Underwriters' counsel
- Ellenoff Grossman & Schole
- Sector
- Biotech & pharma
- Country / state
- MN
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed May 14, 2012
- Latest amendment Aug 27, 2020
- Final prospectus (424B4) Aug 31, 2020
- All filings on EDGAR CIK 1029125
Other Biotech & pharma uplistings in 2020
- Cyclo Therapeutics, Inc.CTDH · Dec 11, 2020 · $12.5M
- Nomad Power Solutions, Inc.LIXT · Nov 27, 2020
- Processa Pharmaceuticals, Inc.PCSA · Oct 5, 2020 · $19.2M
- GeoVax Labs, Inc.GOVX · Sep 28, 2020 · $12.8M
- Biovie Inc.BIVI · Sep 18, 2020 · $15.7M
- Windtree Therapeutics Inc /de/WINTD · May 21, 2020 · $20M